Finance

Beta
Lists
NRSNW:NASDAQ
Neurosense Therapeutics Ltd
$0.14
-3.51%
(-0.0051) 1D
Jun 10, 11:50:42 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NRSNW...
Open
$0.14
High
$0.14
Low
$0.14
Mkt. cap
26.16M
Avg. vol.
1.83K
Volume
0.00
52-wk high
$1.00
52-wk low
$0.07
Beta
4.90
No. of employees
17
Open
$0.14
High
$0.14
Low
$0.14
Mkt. cap
26.16M
Avg. vol.
1.83K
Volume
0.00
52-wk high
$1.00
52-wk low
$0.07
Beta
4.90
No. of employees
17
News stories
From sources across the web
About Neurosense Therapeutics Ltd
CEO-
Employees17
Founded2017
Headquarters-
SectorBiotechnology
Websiteneurosense-tx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1.25M
1.25M
1.86M
1.86M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.09M
1.09M
1.33M
1.33M
Operating expense
2.35M
2.35M
3.20M
3.20M
Total operating expenses
2.35M
2.35M
3.20M
3.20M
Operating income
-2.35M
-2.35M
-3.20M
-3.20M
Other non operating income
-
-
-3.00K
-3.00K
EBT including unusual items
-2.35M
-2.35M
-3.21M
-3.21M
EBT excluding unusual items
-2.35M
-2.35M
-3.21M
-3.21M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-2.35M
-2.35M
-3.21M
-3.21M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
15.00K
15.00K
Interest expense
-8.50K
-8.50K
-
-
Net interest expenses
-8.50K
-8.50K
15.00K
15.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.34M
-2.34M
-3.19M
-3.19M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer